Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracellular Protein Degraders to the Clinic
May 13, 2024 07:00 ET
|
Lycia Therapeutics, Inc.
Lycia Therapeutics has completed a $106.6 million Series C financing to advance its pipeline of LYTAC extracellular protein degraders to the clinic.
Lycia Therapeutics to Present at Jefferies Healthcare Conference
June 05, 2023 07:00 ET
|
Lycia Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced that Aetna Wun Trombley, Ph.D., President and...
Lycia Therapeutics Founder Dr. Carolyn Bertozzi Awarded 2022 Nobel Prize in Chemistry
October 05, 2022 12:52 ET
|
Lycia Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced that founder Carolyn Bertozzi, Ph.D., has been...
Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific Officer
February 28, 2022 07:00 ET
|
Lycia Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent appointment of Steve Staben, Ph.D.,...
Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures
September 09, 2021 07:00 ET
|
Lycia Therapeutics, Inc.
-- Advancing novel targeted therapeutics using its LYTAC protein degradation technology -- -- Plans to use $105 million in recent capital, including $35 million upfront payment from strategic...